30 September 2024

Section 708A Cleansing Statement

This notice is given by PharmAust Limited ACN 094 006 023 (**ASX: PAA**) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

(a) it has today issued 215,000 fully paid ordinary shares (**Shares**) in relation to the exercise of unlisted options, at an exercise price of $0.10 (10 cents) each;

(b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

(c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;

(d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:

(i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

(ii) sections 674 and 674A of the Corporations Act; and

(e) as at the date of this notice, there is no "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

The Appendix 2A relating to the issue of Shares was lodged earlier today.

-Ends-

This announcement is authorised for release by the Board of Directors of PharmAust Limited.

For further information, please contact:

Dr Michael Thurn
Managing Director
investorenquiries@pharmaust.com
P +61 (3) 9692 7222
W www.pharmaust.com

Media:
Jacqueline Pfenninger
Sodali & Co
jacky.pfenninger@sodali.com
P 0447 301 111

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND) and affects both upper and lower motor neurons.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic proteins are broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including ALS.

The company recently announced positive top-line results for its Phase 1 MEND study in participants with ALS. MPL has been selected for inclusion in the HEALEY ALS Platform Trial and anticipates commencing enrolment in Q4 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US FDA for MPL for the treatment of ALS in 2026.

In 2024, the Neurodegenerative Disease Market size is estimated to be worth USD 55.12 billion, with a forecast growth (CAGR) of 7.14% the market size is expected to reach USD 77.82 billion by 2029.[1]

[1] https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market

PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visiting: https://investorhub.pharmaust.com/